-
公开(公告)号:WO1990015620A1
公开(公告)日:1990-12-27
申请号:PCT/US1990003417
申请日:1990-06-15
Applicant: COR THERAPEUTICS, INC.
Inventor: COR THERAPEUTICS, INC. , SCARBOROUGH, Robert, M. , WOLF, David, Lawrence , CHARO, Israel, F.
IPC: A61K37/62
CPC classification number: C07K14/75 , A61K38/12 , A61K38/1703 , A61K38/57 , C07K14/46 , C07K14/755 , C07K14/78
Abstract: An assay for screening snake venom for the presence or absence of platelet aggregation inhibitors (PAIs) based on specific receptor binding is described. Using this assay, the identification and characterization of PAIs in a wide range of snake venom samples was accomplished. The isolated and purified PAI from several of these active snake venoms is described and characterized. In addition, PAIs lacking the Arg-Gly-Asp (RGD) adhesion sequence but containing K* -(G/Sar)-D wherein K* is a modified lysyl residue of the formula R 2 N(CH2)4CHNHCO- wherein each R is independently H, alkyl(1-6C) or at most one R is R -C=NR wherein R is H, alkyl(1-6C), phenyl or benzyl, or is NR in which each R is independently H or alkyl(1-6C) and R is H, alkyl(1-6C), phenyl or benzyl, or R -C=NR is a radical selected from the group consisting of (a), (b), (c) and (d) where m is an integer of 2-3, and each R is independently H or alkyl(1-6C); and wherein one or two (CH2) may be replaced by O or S provided said O or S is not adjacent to another heteroatom are prepared and shown to specifically inhibit the binding of fibrinogen or von Willebrand Factor to GP IIb-IIIa.
Abstract translation: 描述了基于特异性受体结合筛选蛇毒用于存在或不存在血小板聚集抑制剂(PAI)的测定法。 使用该测定,完成了广泛的蛇毒样品中PAIs的鉴定和表征。 描述和表征了来自这些活性蛇毒中的几种的分离和纯化的PAI。 另外,缺少Arg-Gly-Asp(RGD)粘附序列但含有K * - (G / Sar)-D的PAI,其中K *是式R 1 N 2(CH 2)4 CHNHCO- 其中每个R 1独立地是H,烷基(1-6C)或至多一个R 1是R 2 -C = NR 3,其中R 2是H,烷基(1-6C) 或苯基或苄基,或为NR 4,其中每个R 4独立地为H或(1-6C)烷基,R 3为H,烷基(1-6C),苯基或苄基, 2 -C-NR 3是选自(a),(b),(c)和(d)中的基团,其中m是2-3的整数,并且每个R 5是 独立地是H或(1-6C)烷基; 并且其中一个或两个(CH 2)可以被O或S替代,条件是所述O或S不与另一个杂原子相邻,并且显示出特异性抑制纤维蛋白原或血管性血友病因子与GP IIb-IIIa的结合。
-
公开(公告)号:EP0477295A1
公开(公告)日:1992-04-01
申请号:EP90911002.0
申请日:1990-06-15
Applicant: COR THERAPEUTICS, INC.
Inventor: SCARBOROUGH, Robert, M. , WOLF, David, Lawrence , CHARO, Israel, F.
IPC: A61K38 , A61K35 , A61P7 , C07K1 , C07K7 , C07K14 , C12N1 , C12N15 , C12P21 , C12Q1 , G01N33 , C12R1
CPC classification number: C07K14/75 , A61K38/12 , A61K38/1703 , A61K38/57 , C07K14/46 , C07K14/755 , C07K14/78
Abstract: Analyse servant à dépister le venin de serpent pour la présence ou l'absence d'inhibiteurs de l'agrégation des plaquettes (PAIs) à base de liaison de récepteur spécifique. Grâce à cette analyse, l'identification et la caractérisation de PAIs dans un grand nombre d'échantillons de venin de serpent a été accompli. Le PAI isolé et purifié provenant de plusieurs de ces venins de serpent actifs est décrit et caractérisé. D'autre part, les PAI n'ayant pas la séquence d'adhésion Arg-Gly-Asp (RGD) mais contenant K*-(G/Sar)-D où K* est un résidu de lysyle modifié de la formule R12 N(CH2)4CHNHCO- où chaque R1 est indépendamment H, alkyle (1-6) ou tout au plus un R1 est R2-C=NR3 où R2 est H, alkyle (1-6C), phényle ou benzyle, ou est NR42 dans lequel chaque R4 est indépendamment H ou alkyle (1-6C) et R3 est H, alkyle (1-6C), phényle ou benzyle, ou R2-C=NR3 est un radical sélectionné parmi le groupe qui est constitué de (a), (b), (c) et (d) où m est un nombre entier de 2-3, et chaque R5 est indépendamment H ou alkyle (1-6C); et où un ou deux (CH2) peuvent être remplacés par O ou S à condition que lesdits O ou S ne soient pas contigus à un autre hétéroatome, sont préparés et leur action inhibitrice de la liaison du fibrinogène ou du Facteur von Willebrand au GP IIb-IIIa est démontrée.
-
公开(公告)号:EP0477295B1
公开(公告)日:1997-01-02
申请号:EP90911002.5
申请日:1990-06-15
Applicant: COR THERAPEUTICS, INC.
Inventor: SCARBOROUGH, Robert, M. , WOLF, David, Lawrence , CHARO, Israel, F.
IPC: A61K38/54 , C07K1/00 , C07K7/00 , C07K2/00 , G01N33/566
CPC classification number: C07K14/75 , A61K38/12 , A61K38/1703 , A61K38/57 , C07K14/46 , C07K14/755 , C07K14/78
Abstract: An assay for screening snake venom for the presence or absence of platelet aggregation inhibitors (PAIs) based on specific receptor binding is described. Using this assay, the identification and characterization of PAIs in a wide range of snake venom samples was accomplished. The isolated and purified PAI from several of these active snake venoms is described and characterized. In addition, PAIs lacking the Arg-Gly-Asp (RGD) adhesion sequence but containing K* -(G/Sar)-D wherein K* is a modified lysyl residue of the formula R12 N(CH2)4CHNHCO- wherein each R1 is independently H, alkyl(1-6C) or at most one R?1 is R2-C=NR3¿ wherein R2 is H, alkyl(1-6C), phenyl or benzyl, or is NR4 in which each R4 is independently H or alkyl(1-6C) and R3 is H, alkyl(1-6C), phenyl or benzyl, or R2-C=NR3 is a radical selected from the group consisting of (a), (b), (c) and (d) where m is an integer of 2-3, and each R5 is independently H or alkyl(1-6C); and wherein one or two (CH¿2?) may be replaced by O or S provided said O or S is not adjacent to another heteroatom are prepared and shown to specifically inhibit the binding of fibrinogen or von Willebrand Factor to GP IIb-IIIa.
-
-